Table 1.
Demographics and interventional characteristics in the Autologous Conditioned Serum (ACS), ACS+Cortisone (ACS+C), and ACS+C+recombinant IL-1 receptor antagonist protein (ACS+C+rIRAP) groups.
| Characteristic | Total (n=150) |
ACS (n=62) |
ACS+C (n=71) |
ACS+C+rIRAP (n=17) |
P | Effect size | power (1-β) |
Post hoc |
|---|---|---|---|---|---|---|---|---|
| Age | 62.08 ±0.71 | 61.52 ±0.91 | 63.04=1=1.14 | 60.12 ±2.28 | 0.37 | 0.01 (ɳ2) | 0.18 | - |
| Gender (female) | 77 (51.3%) | 30 (48.4%) | 41 (57.7%) | 6 (35.3%) | 0.21 | 0.14 (ω) | 0.31 | - |
| Hip OA localization (left) | 67 (44.7%) | 30 (48.4%) | 31 (43.7%) | 6 (35.3%) | 0.62 | 0.08 (ω) | 0.13 | - |
| Hip prosthesis (yes) | 34 (22.7%) | 4 (6.5%) | 22 (31.0%) | 8 (47.1%) | <0.001 | 0.34 (ω) | 0.97 | - |
| Severe OA (K/L hip grade: 4) | 54 (36.0%) | 16 (25.8%) | 30 (42.3%) | 8 (47.1%) | 0.09 | 0.18 (ω) | 0.49 | - |
| ACS injections | 5.82±0.05 | 5.94±0.03 | 5.70±0.08 | 5.88±0.19 | 0.06 | 0.04 (ɳ2) | 0.59 | - |
| Cortisone injections | - | - | 1.94±0.15 | 2.88±0.32 | <0.01 | 0.08 (ɳ2) | 0.78 | ACS+C<ACS+C+rIRAP |
| rlRAP injections | - | - | - | 3.53±0.26 | - | - | - | |
| Pre-treatment VAS | 6.27±0.18 | 5.50±0.30 | 6.97±0.22 | 6.22±0.60 | <0.001 | 0.09 (ɳ2) | 0.93 | ACS <ACS+C |
| Post-treatment VAS | 3.25±0.20 | 2.58±0.26 | 3.91±0.31 | 2.90±0.53 | <0.01 | 0.07 (ɳ2) | 0.85 | ACS <ACS+C |
N, number of hips; OA, osteoarthritis; VAS, Visual Analogue Scale (0=no pain, 10=most severe pain). The figures represent either M±SE or absolute frequencies (%). For continuous variables, P values were calculated by one-way between-subjects analyses of variance with the effect size ɳ2 (≥0.14= large, ≥0.06=moderate, ≥0.01=small) and Bonferroni-corrected post hoc tests. For dichotomous variables, P values were calculated by Fisher’s exact tests with the effect size ω(≥0.50=large, ≥0.30=moderate, ≥0.10=small). Power ≥0.80=large.